Inventor · disambiguated record
Zhiqiang An
Also filed as: AN ZHIQIANG
40 granted patents·22 pending applications·117 citations·filing 2005–2025
97Inventor score
Top patents by PatentIndex Score
62 records- 0192US7780963B2Anti-ADDL antibodies and uses thereofMERCK & CO INC·Filed 2005·Granted Aug 24, 2010·25 cites·14 claims
- 0291US7754213B2High affinity antibody antagonists of interleukin-13 receptor alpha 1MERCK & CO INC·Filed 2007·Granted Jul 13, 2010·13 cites·7 claims
- 0389US9605057B1Endotrophin neutralization and use thereofUNIV TEXAS·Filed 2014·Granted Mar 28, 2017·5 cites·17 claims
- 0488US10501538B2Anti-LILRB antibodies and their use in detecting and treating cancerUNIV TEXAS·Filed 2017·Granted Dec 10, 2019·5 cites·24 claims
- 0587US7811563B2Anti-addl antibodies and uses thereofUNIV NORTHWESTERN·Filed 2005·Granted Oct 12, 2010·9 cites·14 claims
- 0686US10875912B2EGFL6 specific monoclonal antibodies and methods of their useUNIV TEXAS·Filed 2017·Granted Dec 29, 2020·2 cites·9 claims
- 0785US12202895B2LILRB4 antibodies and uses thereofUNIV TEXAS·Filed 2019·Granted Jan 21, 2025·2 cites·42 claims
- 0885US11912758B2Methods of treating metastasis, including inhibiting bone cancer metastasis, by administering an antibody which binds connexin 43 (Cx43) hemichannelUNIV TEXAS·Filed 2021·Granted Feb 27, 2024·1 cites·20 claims
- 0985US2025145702A1Egfl6 specific monoclonal antibodies and methods of their useUNIV TEXAS·Filed 2024·Application pending·0 cites
- 1084US11629122B2Linkers for antibody drug conjugatesUNIV TEXAS·Filed 2018·Granted Apr 18, 2023·4 cites·18 claims
- 1184US7731962B2Anti-ADDL monoclonal antibody and use thereofMERCK & CO INC·Filed 2006·Granted Jun 8, 2010·8 cites·12 claims
- 1283US12503500B2Connexin 43 (Cx43) hemichannel-binding antibodiesUNIV TEXAS·Filed 2024·Granted Dec 23, 2025·0 cites·8 claims
- 1383US10975142B2Endotrophin neutralization and use thereofUNIV TEXAS·Filed 2019·Granted Apr 13, 2021·1 cites·15 claims
- 1482US12037390B2Leptin antibodies and method of reducing leptinUNIV TEXAS·Filed 2023·Granted Jul 16, 2024·0 cites·4 claims
- 1581US9868777B2CMV neutralizing antigen binding proteinsMERCK SHARP & DOHME·Filed 2014·Granted Jan 16, 2018·4 cites·10 claims
- 1681US9725520B2HER3 specific monoclonal antibodies for diagnostic and therapeutic useUNIV TEXAS·Filed 2014·Granted Aug 8, 2017·4 cites·18 claims
- 1781US8383113B2Anti-ADDL antibodies and uses thereofUNIV NORTHWESTERN·Filed 2012·Granted Feb 26, 2013·4 cites·12 claims
- 1881US7994293B2Antibodies specific for Dkk-1MERCK SHARP & DOHME·Filed 2008·Granted Aug 9, 2011·7 cites·13 claims
- 1979US10358501B2HER3 specific monoclonal antibodies for diagnostic and therapeutic useUNIV TEXAS·Filed 2017·Granted Jul 23, 2019·2 cites·25 claims
- 2079US9371388B2High affinity antibody antagonists of interleukin-13 receptor alpha 1CSL LTD·Filed 2013·Granted Jun 21, 2016·2 cites·4 claims
- 2178US10889637B2Methods of treating an osteolytic tumor and spinal cord injury by administering connexin (Cx) 43 hemichannel-binding antibodiesUNIV TEXAS·Filed 2017·Granted Jan 12, 2021·2 cites·10 claims
- 2276US9777062B2High affinity antibody antagonists of interleukin-13 receptor alpha 1CSL LTD·Filed 2016·Granted Oct 3, 2017·1 cites·10 claims
- 2376US8889138B2Anti-ADDL antibodies and uses thereofACTON PAUL·Filed 2010·Granted Nov 18, 2014·3 cites·12 claims
- 2476US8568722B2High affinity antibody antagonists of interleukin-13 receptor alpha 1NASH ANDREW DONALD·Filed 2010·Granted Oct 29, 2013·2 cites·2 claims
- 2576US8128930B2Anti-ADDL antibodies and uses thereofACTON PAUL·Filed 2010·Granted Mar 6, 2012·3 cites·13 claims
- 2676US8105593B2Anti-ADDL monoclonal antibody and use thereofKINNEY GENE·Filed 2010·Granted Jan 31, 2012·2 cites·12 claims
- 2776US2025042991A1Leptin antibodies and method of reducing leptinUNIV TEXAS·Filed 2024·Application pending·0 cites
- 2875US8420093B2Anti-ADDL monoclonal antibody and use thereofKINNEY GENE·Filed 2012·Granted Apr 16, 2013·2 cites·12 claims
- 2974US12084403B2Linkers for antibody drug conjugatesUNIV TEXAS·Filed 2023·Granted Sep 10, 2024·0 cites·19 claims
- 3074US8207304B2Antibody antagonists of interleukin-13 receptor α1NASH ANDREW DONALD·Filed 2007·Granted Jun 26, 2012·2 cites·6 claims
- 3173US12152071B2EGFL6 specific monoclonal antibodies and methods of their useUNIV TEXAS·Filed 2020·Granted Nov 26, 2024·0 cites·5 claims
- 3272US12331130B2DDR1 antibodies and uses thereofUNIV TEXAS·Filed 2023·Granted Jun 17, 2025·0 cites·13 claims
- 3372US2025115546A1Linkers for antibody drug conjugatesUNIV TEXAS·Filed 2024·Application pending·0 cites
- 3471US11174320B2HER3 specific monoclonal antibodies for diagnostic and therapeutic useUNIV TEXAS·Filed 2019·Granted Nov 16, 2021·0 cites·20 claims
- 3571US8613925B2Anti-IL-13Rα1 antibodies and their uses thereofNASH ANDREW DONALD·Filed 2007·Granted Dec 24, 2013·1 cites·9 claims
- 3670US11760799B2Leptin antibodiesUNIV TEXAS·Filed 2020·Granted Sep 19, 2023·0 cites·4 claims
- 3768US11377491B2Anti-leukocyte-associated immunoglobulin-like receptor 1 (LAIR1) monoclonal antibodies and method of use thereof to treat cancerUNIV TEXAS·Filed 2018·Granted Jul 5, 2022·1 cites·10 claims
- 3867US2025250336A1Novel lilrb4 antibodies and uses thereofUNIV TEXAS·Filed 2025·Application pending·0 cites
- 3965US11498963B2Anti-LILRB antibodies and their use in detecting and treating cancerUNIV TEXAS·Filed 2019·Granted Nov 15, 2022·0 cites·15 claims
- 4064US10221235B2Endotrophin neutralization and use thereofUNIV TEXAS·Filed 2017·Granted Mar 5, 2019·0 cites·16 claims
- 4164US10106617B2High affinity antibody antagonists of interleukin-13 receptor alpha 1CSL LTD·Filed 2017·Granted Oct 23, 2018·0 cites·12 claims
- 4263US12331110B2Monoclonal antibodies against endotrophin and the use thereofUNIV TEXAS·Filed 2019·Granted Jun 17, 2025·0 cites·14 claims
- 4363US2025270312A1Monoclonal antibodies against endotrophin and the use thereofUNIV TEXAS·Filed 2025·Application pending·0 cites
- 4462US2024376199A1Trem2 antigen binding proteins and uses thereofUNIV TEXAS·Filed 2022·Application pending·0 cites
- 4562US2024376222A1Tfr antigen binding proteins and uses thereofUNIV TEXAS·Filed 2022·Application pending·0 cites
- 4660US2024392001A1Lilrb2-specific monoclonal antibodies and methods of their useUNIV TEXAS·Filed 2022·Application pending·0 cites
- 4759US2025172557A1Methods for identifying lilrb ligands and blocking antibodiesUNIV TEXAS·Filed 2023·Application pending·0 cites
- 4858US2023130372A1Novel ddr1 antibodies and uses thereofUNIV TEXAS·Filed 2020·Application pending·0 cites
- 4956US2022267415A1Multimeric sars-cov-2 binding molecules and uses thereofUNIV TEXAS·Filed 2022·Application pending·0 cites
- 5054US2023348586A1Therapeutic agents and uses thereofUNIV TEXAS·Filed 2021·Application pending·0 cites
Showing the top 50 of 62 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Zhiqiang An files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →